Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams Sells 1,181 Shares

Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams sold 1,181 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $17.37, for a total transaction of $20,513.97. Following the completion of the sale, the chief financial officer now owns 8,982 shares in the company, valued at approximately $156,017.34. This trade represents a 11.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Surrozen Price Performance

Shares of NASDAQ:SRZN traded down $2.79 on Monday, hitting $14.23. 197,851 shares of the company traded hands, compared to its average volume of 168,984. Surrozen, Inc. has a 52 week low of $6.00 and a 52 week high of $18.17. The stock has a 50 day simple moving average of $10.92 and a 200-day simple moving average of $9.90.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.77) by $2.33. The firm had revenue of $10.00 million during the quarter. As a group, equities analysts expect that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a research note on Friday.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. CVI Holdings LLC purchased a new position in Surrozen in the 2nd quarter worth about $711,000. Stonepine Capital Management LLC bought a new stake in Surrozen in the 2nd quarter worth approximately $724,000. Nantahala Capital Management LLC purchased a new stake in Surrozen during the 2nd quarter valued at $2,050,000. Finally, Armistice Capital LLC bought a new position in shares of Surrozen during the 2nd quarter valued at $2,080,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.